Search
  • EVI

5th Call for TRANSVAC Vaccine Development Services


TRANSVAC2  project offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease in particular.


TRANSVAC2  project offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease in particular. Except for the few cases indicated on the website, services will be offered free of charge! Academic and non-academic research groups, SMEs and industries can apply but only to service infrastructures outside their own country.

IMPORTANT DATES Opening of the call: 15 February 2019 Submission deadline: 15 April 2019 Evaluation and Selection deadline: 31 May 2019 Feedback to applicants: 1 June 2019

APPLICATION FORM:  More information on the call and the application form can be found here.

Check TRANSVAC2 partners!

iBET (PT, www.ibet.pt) provides services related to mammalian (e.g. HEK293, Vero) and insect (e.g. Sf9 and High Five) cell expression platform screening (TNA1), and production and purification of candidate vaccines at small- (0.2-5L) and pilot-scale (10-50L) (TNA4). Other services available at iBET but not included in the free access is GMP Analytical Services Unit (for QC and batch release) and GMP Mass-Spectroscopy Unit (for QC).


Intravacc  (NL, www.intravacc.nl/ ) provides Access to panel of mutant neisserial LPS derivatives displaying a broad range of TLR4 activity, which can be used as novel adjuvants: https://www.intravacc.nl/media/1188/20170830-intravacc-factsheet-novel-lps-adjuvants.pdf

Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative